Guided Therapeutics (GTHP) Short term Debt (2011 - 2025)

Guided Therapeutics has disclosed Short term Debt across 13 years of filings, most recently posting $37000.0 for Q4 2025.

• Short term Debt for Q4 2025 came in at $37000.0, down 68.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $37000.0 (down 68.64% YoY), and the FY2025 annual result was $37000.0, down 68.64% from the prior year.
• Short term Debt came in at $37000.0 for Q4 2025 at Guided Therapeutics, down from $79000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $1.1 million in Q2 2024 to a low of $17000.0 in Q4 2022.
• The 4-year median for Short term Debt is $60000.0 (2025), against an average of $211933.3.
• Across the five-year window, Short term Debt surged 77.78% in 2022 and tumbled 94.69% in 2025, its largest moves.
• Guided Therapeutics' Short term Debt stood at $88000.0 in 2021, then tumbled by 80.68% to $17000.0 in 2022, then surged by 594.12% to $118000.0 in 2024, then slumped by 68.64% to $37000.0 in 2025.
• The last three Short term Debt figures came in at $37000.0 (Q4 2025), $79000.0 (Q3 2025), and $60000.0 (Q2 2025), per Business Quant data.